TMEM258: A Potential Drug Target Or Biomarker (G746)

Target Name: TMEM258

NCBI ID: G746

TMEM258

TMEM258: A Potential Drug Target Or Biomarker

TMEM258 (Kud) is a protein that is expressed in various tissues of the body, including the brain, heart, kidneys, and liver. It is a member of the transmembrane protein family, which means that it spans the cell membrane and is involved in various cellular processes. TMEM258 has been shown to play a role in a variety of physiological processes, including cell signaling, neurodegeneration, and inflammation. As a result, TMEM258 has potential as a drug target or biomarker.

TMEM258 has been shown to be involved in a number of different signaling pathways. One of the most well-studied functions of TMEM258 is its role in the JAK/STAT signaling pathway. This pathway is involved in the regulation of cell signaling and has been implicated in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. TMEM258 has been shown to play a negative role in this pathway, as it has been shown to inhibit the activity of the JAK enzyme.

Another signaling pathway that is involved in TMEM258's function is the PI3K/AKT signaling pathway. This pathway is involved in the regulation of cell signaling and has been implicated in a variety of diseases, including cancer, neurodegenerative diseases, and cardiovascular disease. TMEM258 has been shown to play a positive role in this pathway, as it has been shown to activate the AKT enzyme.

In addition to its role in these signaling pathways, TMEM258 has also been shown to be involved in the regulation of cellular processes such as cell adhesion, migration, and invasion. These processes are important for the development and progression of many diseases, including cancer, neurodegenerative diseases, and cardiovascular disease.

Given its involvement in these signaling pathways, TMEM258 has potential as a drug target or biomarker. For example, inhibiting the activity of TMEM258 could potentially be a way to treat neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, or Huntington's disease. Additionally, TMEM258 has been shown to be involved in the regulation of cell signaling, which could make it a potential target for cancer therapies.

Furthermore, TMEM258 has also been shown to be involved in the regulation of cellular processes that are important for the development and progression of many diseases, including neurodegenerative diseases and cardiovascular disease. For example, TMEM258 has been shown to play a positive role in the regulation of axon growth and has been implicated in the development of neurodegenerative diseases. Additionally, TMEM258 has been shown to play a negative role in the regulation of blood vessel formation and has been implicated in the development of cardiovascular disease.

In conclusion, TMEM258 is a protein that is involved in a variety of cellular processes and has been shown to play a negative role in the JAK/STAT and PI3K/AKT signaling pathways. As a result, TMEM258 has potential as a drug target or biomarker for a variety of diseases, including neurodegenerative diseases, cancer, and cardiovascular disease. Further research is needed to fully understand the role of TMEM258 in these processes and to develop effective treatments.

Protein Name: Transmembrane Protein 258

Functions: Subunit of the oligosaccharyl transferase (OST) complex that catalyzes the initial transfer of a defined glycan (Glc(3)Man(9)GlcNAc(2) in eukaryotes) from the lipid carrier dolichol-pyrophosphate to an asparagine residue within an Asn-X-Ser/Thr consensus motif in nascent polypeptide chains, the first step in protein N-glycosylation (PubMed:31831667). N-glycosylation occurs cotranslationally and the complex associates with the Sec61 complex at the channel-forming translocon complex that mediates protein translocation across the endoplasmic reticulum (ER). All subunits are required for a maximal enzyme activity (PubMed:26472760, PubMed:27974209). Involved in ER homeostasis in the colonic epithelium (By similarity)

The "TMEM258 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM258 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets